| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,000 | 6,250 | 01.07. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 22,200 | 30 | |||
| 16,000 | 500 | |||
| 15,000 | 15 | |||
| 6,200 | 1.841 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 1.841 | 6,000 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.902 | 0,836 | 2.425 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | 0,000 0,00 % | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | 4basebio Plc - Result of AGM & Issue of Options | 284 | PR Newswire | 4basebio Plc - Result of AGM & Issue of Options
PR Newswire
LONDON, United Kingdom, June 30
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 16.06. | 4basebio Plc - Notice of Investor Presentation | 304 | PR Newswire | 4basebio Plc - Notice of Investor Presentation
PR Newswire
LONDON, United Kingdom, June 16
4basebio... ► Artikel lesen | |
| 15.06. | IN BRIEF: 4basebio appoints Jeff Coller to Strategic Advisory Board | 1 | Alliance News | ||
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 15.06. | 4basebio appoints Dr Jeff Coller to advisory board | 2 | Sharecast | ||
| 15.06. | 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board | 151 | GlobeNewswire (Europe) | Dr. Coller,a Bloomberg Distinguished Professor of RNA Biology and Therapeutics, brings deep expertise to accelerate synthetic DNA and mRNA manufacturingDr. Coller's laboratory team has made seminal... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Novo Nordisk sucht Volumen, BioNTech sucht Beweise | NTG24.de | Pharmaaktien werden derzeit nicht einheitlich bewertet. Der Markt unterscheidet härter zwischen bereits kommerzialisierten Blockbustern, deren Preise unter Druck geraten, und Biotech-Pipelines, die... ► Artikel lesen | |
| 02:58 | Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A) | GlobeNewswire (Europe) | SHANGHAI, July 01, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| Mi | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| Mi | NurExone-Tochter Exo-Top ebnet Weg in den mexikanischen Exosomenmarkt | Small- & Micro Cap Investment | ||
| Mi | Hansa Biopharma AB: Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA | PR Newswire | SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA regionThe transaction significantly... ► Artikel lesen |